Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies-Reference-Cited by-同舟云学术

Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies

Published:2022-12 Issue: Volume:68 Page:104371
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Maniscalco Giorgia Teresa,Liotti Antonietta,Ferrara Anne Lise,Prestipino Elio,Salvatore Simona,Di Battista Maria Elena,Moreggia Ornella,Di Giulio Cesare Daniele,Vastano Roberta,Belardo Martina,Napolitano Massimo,Ranieri Angelo,Longo Katia,Andreone Vincenzo,De Rosa Veronica^ORCID

Funder

Fondazione Italiana Sclerosi Multipla

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference24 articles.

1. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021;Achiron;Mult. Scler.,2021

2. Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: the need for a booster vaccine dose?;Achiron;Eur. J. Intern Med.,2021

3. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord,2021

4. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod;Achiron;J. Neurol.,2022

5. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant;Andrews;N. Engl. J. Med.,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study;BMC Neurology;2024-08-20

2. The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review;Preventive Medicine Reports;2024-08

3. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients;Nature Communications;2024-03-29

4. Metabolic pathways engaged by antigen-specific T and B cells after SARS-CoV-2 vaccination in multiple sclerosis patients on different immunomodulatory drugs reveal immunosenescence and predict vaccine efficacy.;2023-11-17

5. Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy;Vaccines;2023-09-07